EC
PTLA

EcoR1 Capital’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

EcoR1 Capital’s Portfolio PTLA Stock Details PTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-247,858
Closed -$4.84M – 59
2018
Q4 		$4.84M Buy
+247,858
New +$5.1M 0.48% 41

Other funds holding PTLA

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

EcoR1 Capital's PTLA Position: Q1 2019 in Review

EcoR1 Capital sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q1 2019, closing a stake of 247,858 shares — an estimated $4.84M sold.

EcoR1 Capital first reported a position in PTLA in Q4 2018 and held it in 1 quarter. The position peaked at $4.84M in Q4 2018. 209 funds tracked by Wall St. Rank hold PTLA as of Q1 2019.

  • EcoR1 Capital reported no remaining Portola Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • EcoR1 Capital sold 247,858 Portola Pharmaceuticals, Inc. shares in Q1 2019, an estimated $4.84M.
  • EcoR1 Capital first reported a position in Portola Pharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • EcoR1 Capital's Portola Pharmaceuticals, Inc. position peaked at $4.84M in Q4 2018.
  • 209 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q1 2019.

Based on EcoR1 Capital's 13F filing for Q1 2019, filed 15 May 2019.